神经病理性疼痛的药物治疗研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (9): 1076-1080.

• 综述与讲座 • 上一篇

神经病理性疼痛的药物治疗研究进展

李招胜^1,2, 林洪¹, 沙漠¹, 丁真奇¹

¹中国人民解放军第一七五医院,漳州 363000,福建;
²南昌大学医学院,南昌 330000,江西

收稿日期:2013-02-04 修回日期:2013-07-17 发布日期:2013-09-07
通讯作者: 丁真奇,男,教授,博士生导师,研究方向:骨缺损与骨不连。Tel: 13605086327 E-mail: dzqi@xmu.edu.cn
作者简介:李招胜,男,硕士研究生,研究方向:神经病理性疼痛的机制与治疗。Tel: 13695997516 E-mail: lzs1017@163.com

Update in the pharmacotherapy for neuropathic pain treatment

LI Zhao-sheng^1,2, LIN Hong¹, SHA Mo¹, DING Zhen-qi¹

¹The 175th Hospital of PLA, Zhangzhou 363000, Fujian,China;
²Medical College of Nanchang University, Nanchang 330000, Jiangxi,China

Received:2013-02-04 Revised:2013-07-17 Published:2013-09-07

摘要/Abstract

摘要： 神经病理性疼痛是一种神经系统损伤引起的慢性疼痛,严重影响患者的生活质量。药物治疗仍是现用治疗神经病理性疼痛的主要方法。本文综述了现用于治疗神经病理性疼痛主要药物的分子药理机制及其临床运用特点,并在总结疼痛的发生机制的基础上对靶向治疗药物的研发进行了展望。

关键词: 神经病理性疼痛, 药物治疗, 镇痛, 综述

Abstract: Neuropathic pain is a form of chronic pain caused by nervous lesions and significantly reduces patients' quality of life. Nowadays pharmacotherapy is still the main therapeutic paradigm. The article summarizes the underlying molecular pharmacologic mechanisms of the drugs used in the pharmacotherapy as well as their application characteristics in the clinical practice, and points out the perspective of the development of targeted drugs on the basis of elucidating the mechanisms of neuropathic pain.

Key words: Neuropathic Pain, Pharmacotherapy, Analgesic, Review

中图分类号:

R741.02

李招胜, 林洪, 沙漠, 丁真奇. 神经病理性疼痛的药物治疗研究进展[J]. 中国临床药理学与治疗学, 2013, 18(9): 1076-1080.

LI Zhao-sheng, LIN Hong, SHA Mo, DING Zhen-qi. Update in the pharmacotherapy for neuropathic pain treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1076-1080.

参考文献

[1] Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population[J]. Pain, 2008,136(3):380-387.
[2] Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial[J]. Neurology, 2010,74(5):413-420.
[3] Fink K, Meder W, Dooley DJ, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices[J].Br J Pharmacol, 2000,130(4):900-906
[4] Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia[J]. Clin J Pain, 2009,25(4):286-292.
[5] Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin[J]. Pain Med, 2011,12(7):1098-1108.
[6] Berger A, Dukes E, Mercadante S, et al. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain[J]. Eur J Cancer Care (Engl), 2006,15(2):138-145.
[7] Kopsky DJ, Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review[J]. Pain Pract, 2012,12(2):148-153.
[8] Rowbotham MC, Reisner LA, Davies PS, et al. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial[J]. J Pain, 2005,6(11):741-746.
[9] Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain[J]. Eur J Neurol, 2006,13(11):1153-1169.
[10] Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison[J]. Mayo Clin Proc, 2011,86(7):615-626.
[11] Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009,25(7):623-631.
[12] Enomoto T, Yamashita A, Torigoe K, et al. Effects of mirtazapine on sleep disturbance under neuropathic pain-like state[J]. Synapse, 2012,66(6):483-488.
[13] Kanai A, Kumaki C, Niki Y, et al. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia[J]. Pain Med, 2009,10(5):902-909.
[14] Kern KU, Kohl M, Kiefer RT. [Lidocaine patch for therapy of neuropathic and non-neuropathic pain. A clinical case series of 87 patients] [J]. Nervenarzt, 2010,81(12):1490-1497.
[15] Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study[J]. Curr Med Res Opin, 2010,26(7):1607-1619.
[16] Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study[J]. Expert Opin Pharmacother, 2012,13(3):299-311.
[17] Altier N, Dion D, Boulanger A, et al. Management of chronic neuropathic pain with methadone: a review of 13 cases[J]. Clin J Pain, 2005,21(4):364-369.
[18] Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain[J]. Ann Neurol, 2008,64(3):274-283.
[19] 范荣兰,刘双玉,李亚玲,等.A型肉毒毒素治疗带状疱疹后顽固性神经痛20例[J].医药导报,2010,29(11):1452-1453.DOI:10.3870/yydb.2010.11.019.
[20] Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension[J]. Pain Med, 2010,11(4):600-608.
[21] Chen JY, Chang CY, Feng PH, et al. Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain[J]. Clin J Pain, 2009,25(7):562-569.
[22] Gilron I, Bailey J M, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial[J]. Lancet, 2009,374(9697):1252-1261.
[23] Patarica-Huber E, Boskov N, Pjevic M. Multimodal approach to therapy-related neuropathic pain in breast cancer[J]. J BUON, 2011,16(1):40-45.
[24] Mankovsky T, Lynch M, Clark A, et al. Pain catastrophizing predicts poor response to topical analgesics in patients with neuropathic pain[J]. Pain Res Manag, 2012,17(1):10-14.

神经病理性疼痛的药物治疗研究进展

Update in the pharmacotherapy for neuropathic pain treatment

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	毛君, 荣玉, 李炎根, 熊登喜, 赵鹏, 查正江. 氟比洛芬酯在颅脑损伤患者镇痛治疗中的临床应用效果观察及安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1056-1060.
[2]	胡康一, 曹林忠, 万超超, 尚征亚, 杨小瑞, 张勇杰. 基于线粒体功能障碍探讨中药防治激素性股骨头坏死的基础研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 688-696.
[3]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[4]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[5]	苏洋, 周峰, 丁金磊. 艾司氯胺酮复合舒芬太尼对胸腔镜肺癌根治术后情绪及镇痛的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 59-65.
[6]	王欣, 孙合亮, 张庆伟, 刘存明, 王忠云, 杨春. 小剂量艾司氯胺酮在胸腔镜下肺叶切除术患者术后镇痛中的作用[J]. 中国临床药理学与治疗学, 2022, 27(9): 998-1003.
[7]	戴静怡, 王晶晶, 张菁, 郁继诚, 李南洋, 黄志伟. 吸入性甲氧氟烷的临床应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 808-813.
[8]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[9]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[10]	厉永亮, 林海燕, 张玲玲, 董伊隆. 地佐辛自控镇痛泵术前应用对老年下肢骨折患者应激反应及认知功能的影响[J]. 中国临床药理学与治疗学, 2022, 27(3): 302-306.
[11]	伍小霞, 周虎. 瑞芬太尼在重型颅脑外伤患者术后ICU镇静镇痛中的应用[J]. 中国临床药理学与治疗学, 2022, 27(10): 1119-1124.
[12]	卢晓红, 何彩凤, 慈超, 袁涛. 黏膜性类天疱疮治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1197-1200.
[13]	路明, 尹晓玉, 张志清. 间充质干细胞对自身免疫病治疗作用研究进展及机制探究[J]. 中国临床药理学与治疗学, 2021, 26(6): 700-706.
[14]	赵正卿, 李雁鹏, 向小霞, 庄建华, 赵忠新. 慢性失眠的发病机制与认知行为治疗[J]. 中国临床药理学与治疗学, 2021, 26(5): 482-486.
[15]	李雁鹏, 赵正卿, 王雯雯, 庄建华, 赵忠新. 慢性失眠临床诊断与药物治疗研究现状[J]. 中国临床药理学与治疗学, 2021, 26(5): 487-490.